Cargando…

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

BACKGROUND: Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosine, via CD73-mediated catabolism of AMP, contribu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turiello, Roberta, Capone, Mariaelena, Giannarelli, Diana, Morretta, Elva, Monti, Maria Chiara, Madonna, Gabriele, Mallardo, Domenico, Festino, Lucia, Azzaro, Rosa, Levesque, Mitchell P, Imhof, Laurence, Weide, Benjamin, Amaral, Teresa, Chevrier, Marc, Sucker, Antje, Rutkowski, Piotr, Schadendorf, Dirk, Lebbe, Celeste, Luke, Jason John, Wistuba-Hamprecht, Kilian, Dummer, Reinhard, Pinto, Aldo, Morello, Silvana, Ascierto, Paolo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759961/ https://www.ncbi.nlm.nih.gov/pubmed/33361405 http://dx.doi.org/10.1136/jitc-2020-001689

Ejemplares similares

Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
por: Turiello, Roberta, et al.
Publicado: (2022)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
por: Capone, Mariaelena, et al.
Publicado: (2020)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients
por: Galati, Domenico, et al.
Publicado: (2023)

Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis
por: Mallardo, Domenico, et al.
Publicado: (2022)

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
por: Gaißler, Andrea, et al.
Publicado: (2023)

PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
por: Cristinziano, Leonardo, et al.
Publicado: (2022)

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
por: Bochem, Jonas, et al.
Publicado: (2021)

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials
por: Dummer, Reinhard, et al.
Publicado: (2014)

Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer
por: Kim, Miok, et al.
Publicado: (2021)

Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients
por: Tallerico, Rossana, et al.
Publicado: (2015)

CD73: A Promising Biomarker in Cancer Patients
por: Turiello, Roberta, et al.
Publicado: (2020)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
por: Madonna, Gabriele, et al.
Publicado: (2021)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy
por: Mozzillo, Nicola, et al.
Publicado: (2015)

Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer
por: Wistuba-Hamprecht, Kilian, et al.
Publicado: (2020)

Homoarginine, heart failure, and sudden cardiac death in haemodialysis patients
por: Drechsler, Christiane, et al.
Publicado: (2011)

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial
por: Maisel, Alan S., et al.
Publicado: (2011)

Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy
por: Tolosana, Jose María, et al.
Publicado: (2010)

The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction
por: Stahrenberg, Raoul, et al.
Publicado: (2010)

Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device
por: Morley-Smith, Andrew C, et al.
Publicado: (2014)

Test-Retest Reliability of Diffusion Tensor Imaging in Huntington’s Disease
por: Cole, James H., et al.
Publicado: (2014)

Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients
por: Martínez, Goitybell, et al.
Publicado: (2016)

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington’s Disease Patients
por: Szejko, Natalia, et al.
Publicado: (2018)

Natriuretic Peptides in Chronic Heart Failure
por: Brunner-La Rocca, Hans-Peter, et al.
Publicado: (2019)

Biomarkers in Routine Heart Failure Clinical Care
por: Nadar, Sunil K, et al.
Publicado: (2019)

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study
por: Welsh, Paul, et al.
Publicado: (2017)

Relationship between outdoor temperature and cardiovascular disease risk factors in older people
por: Sartini, Claudio, et al.
Publicado: (2016)

Variability of biomarkers in patients with chronic heart failure and healthy controls
por: Meijers, Wouter C., et al.
Publicado: (2016)

Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease
por: Pontillo, Claudia, et al.
Publicado: (2017)

Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2017)

The clinical utility of kinetic glomerular filtration rate
por: O'Sullivan, Eoin D., et al.
Publicado: (2017)

Serum levels of selected cytokines [interleukin (IL)-17A, IL-18, IL-23] and chemokines (RANTES, IP10) in the acute phase of immunoglobulin A vasculitis in children
por: Jaszczura, Majka, et al.
Publicado: (2019)

Identifying and Characterizing Stress Pathways of Concern for Consumer Safety in Next-Generation Risk Assessment
por: Hatherell, Sarah, et al.
Publicado: (2020)

Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium
por: Bahls, Martin, et al.
Publicado: (2019)

Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study
por: Opinc, Aleksandra, et al.
Publicado: (2020)

Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review
por: Henkens, Michiel T.H.M., et al.
Publicado: (2020)

A combined bioinformatics, experimental and clinical approach to identify novel cardiac‐specific heart failure biomarkers: is Dickkopf‐3 (DKK3) a possible candidate?
por: Piek, Arnold, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pd8j4lv96d44mhn2fe7udomb44